Endoscopic screening for identification of signet ring cell gastric cancer foci in carriers of germline pathogenic variants in CDH1.

CDH1 Endoscopy Gastrectomy Hereditary diffuse gastric cancer Surveillance

Journal

Familial cancer
ISSN: 1573-7292
Titre abrégé: Fam Cancer
Pays: Netherlands
ID NLM: 100898211

Informations de publication

Date de publication:
11 Sep 2024
Historique:
received: 02 06 2024
accepted: 03 09 2024
medline: 12 9 2024
pubmed: 12 9 2024
entrez: 11 9 2024
Statut: aheadofprint

Résumé

To determine the preoperative detection of signet ring cancer cells (SRC) on upper endoscopy (EGD) in patients with CDH1 pathogenic variant (PV) undergoing gastrectomy. To evaluate the development of advanced diffuse gastric cancer (DGC) in patients choosing surveillance. Guidelines recommend prophylactic total gastrectomy (pTG) in CDH1 PV carriers with family history of DGC between 18 and 40 years. Annual EGD with biopsies according to established protocols is recommended in carriers with no SRC and no family history of DGC, with consideration of pTG. Retrospective analysis of asymptomatic patients with CDH1 PVs with ≥ 1 surveillance EGD. Outcomes included pre-operative EGD detection of SRC, surgical stage, and progression to advanced DGC in those electing surveillance with EGD. 48 patients with CDH1 PVs who had ≥ 1 EGD were included. 24/ 48 (50%) underwent gastrectomy, including pTG in 7 patients. SRCC were detected on gastrectomy specimen in 21/24 (87.5%). SRCs were identified by EGD in 17/21 patients who had SRCC on gastrectomy specimens (sensitivity 81%, 17/21). All cancers were stage pT1a. The remaining 17 patients (50% with a family history of gastric cancer) continue in annual EGD surveillance with a median follow-up of 34.6 months. No SRCC or advanced DGC have been diagnosed. No CDH1 PV carriers without SRCC on random biopsies followed in an endoscopic program developed advanced DGC over a median follow up of 3 years. In the short term, EGD surveillance might be a safe alternative to immediate pTG in experienced hands in referral centers.

Identifiants

DOI: 10.1007/s10689-024-00421-z PMID: 39261344
pubmed: 39261344
doi: 10.1007/s10689-024-00421-z
pii: 10.1007/s10689-024-00421-z
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

© 2024. The Author(s).

Références

Roberts ME, Ranola JMO, Marshall ML et al (2019) Comparison of CDH1 Penetrance estimates in clinically ascertained families vs families ascertained for multiple gastric cancers. JAMA Oncol 5(9):1325–1331. https://doi.org/10.1001/jamaoncol.2019.1208
doi: 10.1001/jamaoncol.2019.1208 pubmed: 31246251 pmcid: 6604087
Xicola RM, Li S, Rodriguez N et al (2019) Clinical features and cancer risk in families with pathogenic CDH1 variants irrespective of clinical criteria. J Med Genet 56(12):838–843. https://doi.org/10.1136/jmedgenet-2019-105991
doi: 10.1136/jmedgenet-2019-105991 pubmed: 31296550
Ryan CE, Fasaye GA, Gallanis AF et al (2024) Germline CDH1 Variants and Lifetime Cancer Risk. JAMA. Jun 14. https://doi.org/10.1001/jama.2024.10852 . Epub ahead of print. PMID: 38873722
Vos EL, Salo-Mullen EE, Tang LH et al (2020) Indications for total gastrectomy in CDH1 mutation carriers and outcomes of risk-reducing minimally invasive and open gastrectomies. JAMA Surg 155(11):1050–1057. https://doi.org/10.1001/jamasurg.2020.3356
doi: 10.1001/jamasurg.2020.3356 pubmed: 32997132
Friedman M, Adar T, Patel D et al (2021) Surveillance Endoscopy in the management of Hereditary diffuse gastric Cancer syndrome. Clin Gastroenterol Hepatol 19(1):189–191. https://doi.org/10.1016/j.cgh.2019.10.033
doi: 10.1016/j.cgh.2019.10.033 pubmed: 31678201
Laszkowska M, Tang L, Vos E et al (2023) Factors Associated with detection of Hereditary diffuse gastric Cancer on Endoscopy in individuals with germline CDH1 mutations. Gastrointest Endosc S0016–5107. https://doi.org/10.1016/j.gie.2023.04.2071
Lee CYC, Olivier A, Honing J et al (2023) Endoscopic surveillance with systematic random biopsy for the early diagnosis of hereditary diffuse gastric cancer: a prospective 16-year longitudinal cohort study. Lancet Oncol 24(1):107–116. https://doi.org/10.1016/S1470-2045(22)00700-8
doi: 10.1016/S1470-2045(22)00700-8 pubmed: 36509094
Chen Y, Kingham K, Ford JM et al (2011) A prospective study of total gastrectomy for CDH1-positive hereditary diffuse gastric cancer. Ann Surg Oncol 18(9):2594–2598. https://doi.org/10.1245/s10434-011-1648-9
doi: 10.1245/s10434-011-1648-9 pubmed: 21424370
Mi EZ, Mi EZ, di Pietro M et al (2018) Comparative study of endoscopic surveillance in hereditary diffuse gastric cancer according to CDH1 mutation status. Gastrointest Endosc 87(2):408–418. https://doi.org/10.1016/j.gie.2017.06.028
doi: 10.1016/j.gie.2017.06.028 pubmed: 28688938 pmcid: 5780354
Jacobs MF, Dust H, Koeppe E et al (2019) Outcomes of Endoscopic Surveillance in individuals with genetic predisposition to Hereditary diffuse gastric Cancer. Gastroenterology 157(1):87–96. https://doi.org/10.1053/j.gastro.2019.03.047
doi: 10.1053/j.gastro.2019.03.047 pubmed: 30935944
Van Dieren JM, Kodach LL, Den Hartog P et al (2020) Gastroscopic surveillance with targeted biopsies compared with random biopsies in CDH1 mutation carriers. Endoscopy 52(10):839–846. https://doi.org/10.1055/a-1157-8678
doi: 10.1055/a-1157-8678 pubmed: 32408363
Asif B, Sarvestani AL, Gamble LA et al (2023) Cancer surveillance as an alternative to prophylactic total gastrectomy in hereditary diffuse gastric cancer: a prospective cohort study. Lancet Oncol 24(4):383–391. https://doi.org/10.1016/S1470-2045(23)00057-8
doi: 10.1016/S1470-2045(23)00057-8 pubmed: 36990610 pmcid: 10084814
Blair VR, McLeod M, Carneiro F et al (2020) Hereditary diffuse gastric Cancer: updated clinical practice guidelines. Lancet Oncol 21(8):1–32. https://doi.org/10.1016/S1470-2045(20)30219-9
doi: 10.1016/S1470-2045(20)30219-9
Yamashina M (1986) Early gastric carcinoma. Cancer 58(6):1333–1339. https://doi.org/10.1002/1097-0142(19860915)58:6%3C1333::aid-cncr2820580625%3E3.0.co;2-b
Hu Y, Vos EL, Baser RE et al (2021) Longitudinal analysis of Quality-of-life recovery after gastrectomy for Cancer. Ann Surg Oncol 28(1):48–56. https://doi.org/10.1245/s10434-020-09274-z
doi: 10.1245/s10434-020-09274-z pubmed: 33125569
Fujita H, Lennerz JKM, Chung DC et al (2012) Endoscopic surveillance of patients with hereditary diffuse gastric cancer: biopsy recommendations after topographic distribution of cancer foci in a series of 10 CDH1-mutated gastrectomies. Am J Surg Pathol 36(11):1709–1717. https://doi.org/10.1016/j.ypat.2012.11.042
doi: 10.1016/j.ypat.2012.11.042 pubmed: 23073328
Lim YC, Di Pietro M, O’Donovan M et al (2014) Prospective cohort study assessing outcomes of patients from families fulfilling criteria for hereditary diffuse gastric cancer undergoing endoscopic surveillance. Gastrointest Endosc 80(1):78–87. https://doi.org/10.1016/j.gie.2013.11.040
doi: 10.1016/j.gie.2013.11.040 pubmed: 24472763
Benesch MGK, Bursey SR, O’connell AC et al (2021) Cdh1 gene mutation hereditary diffuse gastric cancer outcomes: analysis of a large cohort, systematic review of endoscopic surveillance and secondary cancer risk postulation. Cancers (Basel) 13(11):1–18. https://doi.org/10.3390/cancers13112622
doi: 10.3390/cancers13112622
Pappas A, Tan WK, Waldock W et al (2021) Single-bite versus double-bite technique for mapping biopsies during endoscopic surveillance for hereditary diffuse gastric cancer: a single-center, randomized trial. Endoscopy 53(3):246–253. https://doi.org/10.1055/a-1201-3125
doi: 10.1055/a-1201-3125 pubmed: 32679601
Curtin BF, Gamble LA, Schueler SA et al (2021) Enhanced endoscopic detection of occult gastric cancer in carriers of pathogenic CDH1 variants. J Gastroenterol 56(2):139–146. https://doi.org/10.1007/s00535-020-01749-w
doi: 10.1007/s00535-020-01749-w pubmed: 33206267
Hebbard PC, MacMillan A, Huntsman D et al (2009) Prophylactic total gastrectomy (PTG) for hereditary diffuse gastric cancer (HDGC): the Newfoundland experience with 23 patients. Ann Surg Oncol 16(7):1890–1895. https://doi.org/10.1245/s10434-009-0471-z
doi: 10.1245/s10434-009-0471-z pubmed: 19408054
Hüneburg R, Marwitz T, van Heteren P et al (2016) Chromoendoscopy in combination with random biopsies does not improve detection of gastric cancer foci in CDH1 mutation positive patients. Endosc Int Open 04(12):E1305–E1310. https://doi.org/10.1055/s-0042-112582
doi: 10.1055/s-0042-112582
Kumar S, Katona BW, Long JM et al (2020) Endoscopic Ultrasound has limited utility in diagnosis of gastric Cancer in carriers of CDH1 mutations. Clin Gastroenterol Hepatol 18(2):505–508e1. https://doi.org/10.1016/j.cgh.2019.04.064
doi: 10.1016/j.cgh.2019.04.064 pubmed: 31077828
Schueler SA, Gamble LA, Curtin BF et al (2021) Evaluation of confocal laser endomicroscopy for detection of occult gastric carcinoma in CDH1 variant carriers. J Gastrointest Oncol 12(2):216–225. https://doi.org/10.21037/jgo-20-430
doi: 10.21037/jgo-20-430 pubmed: 34012620 pmcid: 8107576
Oliveira C, Sousa S, Pinheiro H et al (2009) Quantification of epigenetic and genetic 2nd hits in CDH1 during Hereditary diffuse gastric Cancer syndrome progression. Gastroenterology 136(7):2137–2148. https://doi.org/10.1053/j.gastro.2009.02.065
doi: 10.1053/j.gastro.2009.02.065 pubmed: 19269290

Auteurs

Lady Katherine Mejia Perez (LK)

Department of Gastroenterology, Hepatology and Nutrition Digestive Disease and Surgical Institute, Cleveland Clinic, Desk A30, 9500 Euclid Avenue, Cleveland, OH, 44195, USA.

Margaret O'Malley (M)

Department of Colorectal Surgery, Cleveland Clinic, Cleveland, OH, USA.
Sanford R. Weiss MD Center for Hereditary Colorectal Neoplasia, Cleveland Clinic, Cleveland, OH, USA.

Arjun Chatterjee (A)

Department of Internal Medicine, Cleveland Clinic, Cleveland, OH, USA.

Ruishen Lyu (R)

Department of Quantitative Health Sciences, Cleveland Clinic, Cleveland, OH, USA.

Qijun Yang (Q)

Department of Quantitative Health Sciences, Cleveland Clinic, Cleveland, OH, USA.

Michael W Cruise (MW)

Sanford R. Weiss MD Center for Hereditary Colorectal Neoplasia, Cleveland Clinic, Cleveland, OH, USA.
Department of Pathology and Lab Medicine, Cleveland Clinic, Cleveland, OH, USA.

Lisa LaGuardia (L)

Department of Colorectal Surgery, Cleveland Clinic, Cleveland, OH, USA.
Sanford R. Weiss MD Center for Hereditary Colorectal Neoplasia, Cleveland Clinic, Cleveland, OH, USA.

David Liska (D)

Department of Colorectal Surgery, Cleveland Clinic, Cleveland, OH, USA.
Sanford R. Weiss MD Center for Hereditary Colorectal Neoplasia, Cleveland Clinic, Cleveland, OH, USA.

Carole Macaron (C)

Department of Gastroenterology, Hepatology and Nutrition Digestive Disease and Surgical Institute, Cleveland Clinic, Desk A30, 9500 Euclid Avenue, Cleveland, OH, 44195, USA.
Sanford R. Weiss MD Center for Hereditary Colorectal Neoplasia, Cleveland Clinic, Cleveland, OH, USA.

R Matthew Walsh (RM)

Sanford R. Weiss MD Center for Hereditary Colorectal Neoplasia, Cleveland Clinic, Cleveland, OH, USA.
Department of General Surgery, Cleveland Clinic, Cleveland, OH, USA.

Carol A Burke (CA)

Department of Gastroenterology, Hepatology and Nutrition Digestive Disease and Surgical Institute, Cleveland Clinic, Desk A30, 9500 Euclid Avenue, Cleveland, OH, 44195, USA. burkec1@ccf.org.
Department of Colorectal Surgery, Cleveland Clinic, Cleveland, OH, USA. burkec1@ccf.org.
Sanford R. Weiss MD Center for Hereditary Colorectal Neoplasia, Cleveland Clinic, Cleveland, OH, USA. burkec1@ccf.org.

Classifications MeSH